The Kenya BioVax Institute (KBI) by the Ministry of Health has today named Michael Lusiola as the Chief Executive Officer.
Lusiola succeeds Rabera Kenyanya, who has been serving as acting CEO since December 2021.
According to the Ministry, Lusiola is a senior healthcare executive and pharmaceutical industry leader with extensive experience.
“A pharmaceutical research and development business executive with over 20 years experience in a multinational setting. Dr. Lusiola brings to BioVax a wealth of extraordinary medical-scientific knowledge and expertise as a dynamic and respected leader having most recently worked as a VP in global clinical development at AstraZeneca Pharmaceuticals, UK and USA,” MoH stated.
As a dynamic and renowned leader, he brings a wealth of remarkable medical-scientific knowledge and skills, having most recently worked as a VP in global clinical development (immunotherapies) at AstraZeneca Pharmaceuticals, UK and USA.
Lusiola is a pharmaceutical research and development company executive with over 20 years of expertise.
Mutahi Kagwe, the Health Cabinet Secretary, inaugurated the Kenya BioVax Institute board in December 2021.
It was planned to start producing vaccines in April of this year.
In January, KBI released the prerequisites for the person who will oversee the institute’s day-to-day operations.
“The ideal candidate must have at least 12 years of demonstrable leadership experience in medicine, pharmaceutical production, manufacturing and marketing and innovation,” the board said in an advertisement.
